And to keep the facts solid he also stated that they have been in active discussions with several of the leading generic and speciality pharma companies and anticipates finalizing a commercialization agreement soon. Can't wait for pay day!!
"So we now turn our focus towards the commercialization of CPI-300, with the objective of a product launch with a partner by the second quarter of 2012." Here is a qoute from the CEO in the FDA approval PR release. IMO this is not an admission of partnership or even a solid product launch date but simply goals. Hopefully igxt reaches these goals next year.